1. Different diabetogenic effect of statins according to intensity and dose in patients with acute myocardial infarction: a nationwide cohort study
- Author
-
Jieun Lee, Jah Yeon Choi, Byoung Geol Choi, You-Jung Choi, Soohyung Park, Dong Oh Kang, Eun Jin Park, Ji Bak Kim, Seung Young Roh, Jin Oh Na, Cheol Ung Choi, Eung Ju Kim, Chang Gyu Park, Myung Ho Jeong, Jin-Yong Hwang, Seung-Ho Hur, Jin-Ok Jeong, SeokKyu Oh, Seung-Woon Rha, and KAMIR NIH Investigators
- Subjects
Statin intensity ,New-onset diabetes mellitus ,Acute myocardial infarction ,Medicine ,Science - Abstract
Abstract Statin is crucial for acute myocardial infarction (AMI) patients. However, the risk of new-onset diabetes mellitus (NODM) associated with statin is a concern. This study aimed to determine the incremental diabetogenic effects of statins according to their intensity and dose in AMI patients undergoing percutaneous coronary intervention (PCI). Among 13,104 patients enrolled in the Korea AMI Registry between 2011 and 2015, 6152 patients without diabetes mellitus (DM) who underwent PCI and received moderate-to-high-intensity atorvastatin and rosuvastatin were selected for the study. The endpoints were NODM and major adverse cardiovascular events (MACE), composite of all-cause mortality, recurrent MI, and revascularization up to 3 years. Among the participants, 3747 and 2405 received moderate- and high-intensity statins, respectively. The Kaplan–Meier curves demonstrated a higher incidence of NODM in patients with high-intensity statins than those with moderate-intensity. High-intensity statin was a significant predictor of NODM after adjusting for other co-variables (HR = 1.316, 95% CI 1.024–1.692; P
- Published
- 2024
- Full Text
- View/download PDF